What is EpigenDx?
EpigenDx operates at the intersection of advanced genomics and clinical diagnostics, specializing in the critical field of DNA methylation analysis. The company provides a comprehensive suite of products and specialized laboratory services designed to support researchers in deciphering complex epigenetic patterns. With deep technical expertise in Pyrosequencing and bisulfite sequencing, EpigenDx serves as a vital infrastructure provider for the scientific community, enabling high-precision molecular diagnosis and the identification of novel disease biomarkers. Its commitment to rigorous quality standards has established it as a trusted partner for government, academic, and commercial research entities seeking to push the boundaries of epigenomic science.
How much funding has EpigenDx raised?
EpigenDx has raised a total of $46K across 1 funding round:
Debt
$46K
Debt (2021): $46K with participation from PPP
Key Investors in EpigenDx
PPP
Public-Private Partnership
What's next for EpigenDx?
With the infusion of this recent capital, EpigenDx is poised to transition into a more aggressive growth phase, likely focusing on the commercialization of its diagnostic pipeline and the expansion of its technical infrastructure. The company's strategic roadmap suggests a shift toward scaling its service capacity to meet the rising demand for high-throughput epigenetic analysis in clinical settings. By deepening its investment in proprietary research methodologies, EpigenDx aims to solidify its market leadership, potentially exploring new therapeutic areas where DNA methylation serves as a primary indicator for disease progression and treatment efficacy. This trajectory reflects a mature approach to scaling, balancing technical innovation with the operational requirements of a high-growth biotech enterprise.
See full EpigenDx company page
